To evaluate the risk of priapism in patients undergoing Dynamic-Penile duplex ultrasound (D-PDU) who were referred to our Unit between January 2022 and December 2023. We enrolled 292 patients, of whom 268 underwent Dynamic-Penile duplex ultrasound for erectile dysfunction and 24 for Peyronie's disease. The mean age of the patients was 56±12 years, the mean alprostadil dose administered was 9.17±5.59 mcg and the mean erection response was 79.55±19.95%. To evaluate the occurrence of priapism, we considered i) patients who called our phone number within the first hours following the exam; ii) patients who were referred to our Emergency Department within the 24h following Dynamic-Penile duplex ultrasound; iii) patients who reported to us the occurrence of priapism at subsequent follow-up visit; iv) patients who e-mailed us to report this side effect. We found no cases of priapism (0/292 patients, 0%). Therefore, statistical analysis with correlation and regression analysis was not conducted. In our opinion, the risk of priapism following Dynamic-Penile duplex ultrasound with alprostadil injection might be re-evaluated, as it appears to be a rare and preventable condition.
Read full abstract- All Solutions
Editage
One platform for all researcher needs
Paperpal
AI-powered academic writing assistant
R Discovery
Your #1 AI companion for literature search
Mind the Graph
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus - Support
Overview
45725 Articles
Published in last 50 years
Articles published on Rare Condition
Authors
Select Authors
Journals
Select Journals
Duration
Select Duration
30418 Search results
Sort by Recency